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Abstract
Objective: To compare clinical and labora-
tory data of leprosy patients diagnosed in 
specialized services in the State of Mato 
Grosso, Brazil, during the initial treatment 
and the retreatment of relapse. Methods: 
A cross-sectional study of patients with 
diagnosis of leprosy relapse was conducted 
in specialized health services of five cities, 
between 2005 and 2007. Initial treatment 
was described as t1 and relapse treatment 
as t2. Data Source: Sistema de Informação de 
Agravos de Notificação (Sinan – Reportable 
Diseases Information System), medical 
records, laboratory tests, and files of in-
dividual reports and of physical disability 
assessments. The chi-square test (c2) was 
applied at a significance level of 5%. Results: 
The clinical dimorphic form prevailed in t2 
when compared with t1 (39.6% versus 11.3%; 
p = 0.003); 20.8% of relapse cases showed a 
bacilloscopy index ≥ 4+ in relation to those 
in t1 (p = 0.034)]; an increase in the num-
ber of (17%) cases of relapse with physical 
disability at level 0 was found, compared 
to patients evaluated during the diagnosis 
(58.5% versus 41.5%); an increase (7.5%) in 
the recurrence of disabilities at level 2 was 
observed, when compared to t1 (9.4% versus 
a 9%); and there was a higher prevalence 
of cases not evaluated for disability be-
tween t1 (45.3%) and t2 (22.6%) (p = 0.040). 
Conclusion: Cases of relapse characterized 
the aggravation of the disease, indicated by 
the increase in the bacilloscopy index and 
level of physical disability. Attention should 
be paid to the diagnostic confirmation of 
relapse using bacilloscopy tests, especially 
in multibacillary cases, and systematic neu-
rological assessment of all leprosy patients. 
Keywords: Leprosy. Relapse. Epidemiology. 
Cross-Sectional Studies. Prevention and 
Control. Disease Reporting.
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Resumo
Objetivo: Comparar as características 
clínico-laboratoriais dos doentes de han-
seníase durante o tratamento inicial e no 
retratamento por recidiva diagnosticada em 
unidades de saúde de referência no Estado 
de Mato Grosso Método: Estudo transver-
sal de casos diagnosticados de recidiva em 
hanseníase em unidades de referência de 
2005 a 2007 em cinco municípios do Estado. 
O tratamento inicial foi considerado t1 e 
a recidiva t2. Fontes de dados: Sistema de 
Informação de Agravos de Notificação, 
prontuários, exames laboratoriais, ficha 
de notificação individual e de avaliação 
de incapacidade física. Utilizou-se para 
a comparação e cálculo de proporções o 
teste do Qui-quadrado (c2) ao nível de sig-
nificância de 5%. Resultados: Verificou-se 
predomínio da forma clínica dimorfa em 
t2 quando comparada a t1 (39,6% versus 
11,3%; p = 0,003); 20,8%, dos casos em re-
cidivas apresentaram índice baciloscópico 
≥ 4+ se comparados aqueles em t1 (p = 
0,034); aumento (17%) dos casos de recidiva 
com grau zero de incapacidade quando 
comparados aos pacientes avaliados no 
momento do diagnóstico (58,5% versus 
41,5%); aumento (7,5%) de recidivas com 
incapacidades grau 2 quando comparadas a 
t1 (9,4% versus 1, 9%); predomínio de casos 
não avaliados quanto a incapacidade física 
entre t1 (45,3%) e t2 (22,6%); (p = 0,040). 
Conclusão: Os casos de recidiva caracter-
izam o agravamento da doença indicadas 
pelo aumento do índice baciloscópico e do 
grau de incapacidade física. Recomenda-se 
maior atenção à confirmação diagnóstica de 
recidiva por meio de exames baciloscópicos, 
em especial nos multibacilares, e da aval-
iação neurológica sistemática de todos os 
pacientes de hanseníase.
Palavras-chaves: Hanseníase. Recidiva. 
Epidemiologia. Estudos transversais. 
Prevenção e Controle. Notificação de 
Agravos.
Introduction
Currently, there are 228,474 cases of lep-
rosy worldwide. Brazil contributes to 92.4% 
of all cases recorded in the Americas and it 
ranks second in absolute number of cases, 
only surpassed by India1.
Between 2004 and 2010, there were 2,596 
cases of leprosy recurrence on a global level. 
In Brazil, in 2009 alone, there were 1,483 
cases of recurrence, totaling 3.9% of the 
increase in cases during this period2. 
According to parameters of 2011 the 
state of Mato Grosso, in the Center-West 
region of Brazil, is a hyper-endemic area 
with 2,569 new cases and a general detection 
coefficient of 84.6/100,000 inhabitants, with 
significant differences among distinct areas 
of this state3,4,5. 
Since the 1980s, the World Health 
Organization (WHO) has recommended 
the use of polychemotherapy (PCT) and this 
measure has led to the treatment and cure of 
more than 14 million patients with leprosy6.
Although the recommended treatment 
is effective, there has been evidence of pos-
sible resistance to the existing chemothera-
peutic drugs. This has been proved experi-
mentally by Pettit and Rees (1964), using the 
inoculation technique with Mycobacterium 
leprae standardized by Shepard (1960). The 
result associated with the irregular use of the 
previously mentioned therapeutic scheme 
leads to low adherence to treatment and the 
possibility of occurrence of leprosy recur-
rence and, consequently, the permanence of 
the source of infection in the community7-10.
The fact that M. leprae is not cultivated 
in vitro makes it difficult to define the pa-
rameters for laboratory confirmation of the 
initial diagnosis, treatment efficacy moni-
toring and leprosy recurrence11-13.
There is no consensus on the criteria 
established for the diagnostic confirma-
tion of recurrence. The following variations 
are included: reappearance of new lesions 
and/or nerve injuries with clinical and his-
topathological signs consistent with active 
forms (borderline-borderline/BB, border-
line-lepromatous/BL and lepromatous/LL), 
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according to Ridley-Jopling’s classification 
(1966)14,15; new skin lesions; increase in the 
bacilloscopy index (BI) >2+ in one or more 
areas; and viability of M. leprae through 
inoculation in mice paw16; reactivation 
after six months of regular treatment with 
multi-drug therapy; anesthetic lesions and/
or exacerbation of previous lesions; bacte-
riological evidence with or without clini-
cal activity; nerve lesions with or without 
neuritis in cases of paucibacillary leprosy; 
and diagnostic confirmation with biopsy17; 
reactivation and presence of new anesthetic 
lesions confirmed with bacilloscopy exam 
and skin biopsy18.
Studies aimed at the technical-scientific 
support and infrastructure available for 
professionals to accurately diagnose recur-
rence in health services are essential. The 
present study aimed to compare the clinical 
and laboratory characteristics of individu-
als with leprosy during the initial treatment 
and during new treatment of recurrence 
diagnosed in referral health clinics of the 
state of Mato Grosso. 
Materials and Methods
A cross-sectional epidemiological study 
was conducted to analyze cases of lep-
rosy recurrence diagnosed in referral health 
clinics of five cities of the state of Mato 
Grosso (Cáceres, Cuiabá, Diamantino, 
Rondonópolis and Várzea Grande) between 
2005 and 2007. There are 1,032,523 inhabit-
ants in these five cities, 36.2% of the total 
state population estimated to be 2,854,462 
inhabitants at the time of this study19. 
The criteria for the diagnosis of recur-
rence used in specialized health clinics are 
defined in the protocols adopted by the 
Brazilian Ministry of Health11: patients who 
were discharged as cured subsequently had 
new lesions and/or the exacerbation of pre-
vious lesions, new neurological lesions with 
an unsatisfactory response after treatment 
with corticosteroids and/or thalidomide, 
and results of bacilloscopy/histopathologi-
cal tests compatible with active forms. 
The comparative analysis of the 
investigated groups included the cases 
diagnosed as recurrence, which were de-
scribed as time 2 (t2) and recorded in the 
databases of the Sistema de Informação de 
Agravos de Notificação (Sinan/MT – State 
of Mato Grosso Information System for 
Notifiable Diseases) between January 1st 
2005 and December 31st 2007, in the cities 
selected for this study. Of all 82 cases of re-
currence reported in this period, 53 (64.6%) 
were considered to be occurrences of lep-
rosy recurrence with the validation of the 
information found in the medical records 
available in the specialized treatment units. 
The exclusion of 29 individuals was due to 
transfers to other states and diagnostic er-
rors. The initial treatment group or time 1 
(t1) included the records of leprosy cases 
that had been discharged as cured before 
the recurrence under study occurred. The 
sources of data were as follows: Sinan/lep-
rosy/MT, medical records, laboratory tests, 
individual report files and physical disability 
assessment. Laboratory tests of bacilloscopy 
and histopathology were performed in the 
state and municipal Laboratório Central de 
Saúde Pública (Central Laboratory of Public 
Health) and in the Instituto Lauro de Souza 
Lima de Bauru - São Paulo (ILSL), respec-
tively. The study variables were the following 
clinical/laboratory characteristics: clinical 
form, number, type and location of lep-
rosy lesion, nerve thickness, reactive state, 
adverse effects, bacilloscopy and histopa-
thology, and level of physical disability as 
assessed during diagnosis.
The non-inclusion of ill patients diag-
nosed as recurrence in all state health clinics 
is justified by the fact that 80% of these di-
agnoses are made in primary health clinics, 
which do not have appropriate technical 
resources. Consequently, the inclusion of 
such cases could create selection bias and 
thus affect the study5. 
The SPSS 15 software program was 
used to manage and analyze data. Double 
data entry was used to check data consis-
tency. The chi-square test (c2) and a sig-
nificance level of 5% were used to compare 
proportions.
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The present research project was as-
sessed and approved by the Research Ethics 
Committee of the Hospital Universitário 
Júlio Muller (CEP/HUJM – Júlio Muller 
University Hospital – process 321 of April 
2007). 
Results
Of the 53 cases of recurrence reported 
in the state of Mato Grosso between 2005 
and 2007, the majority were males (66.0%, 
n=35) with a mean age of 46.3 years (±16.8; 
minimum age of 18 and maximum age of 
82 years). The mean time interval between 
the initial treatment and the occurrence of 
leprosy recurrence was seven years and six 
months (Table 1).
Table 2 shows the results of the compara-
tive analysis of the proportion of leprosy 
cases between initial treatment (t1) and 
recurrence (t2), according to clinical form, 
bacilloscopy, histopathology and level of 
physical disability. The group of cases in this 
study revealed a higher proportion of cases 
of recurrence with the dimorphic clinical 
form (39.6%), whereas these represented 
11.3% of all cases in t1. In contrast, 9.4% 
and 13.2% of individuals in t2 were catego-
rized in the undetermined and tuberculoid 
clinical forms, respectively, and of these, 
13.2% and 20.8% were in the same catego-
ries in t1 [c2 = 16.06 (p= 0.003)]. With regard 
to the characteristic of the bacilloscopy 
tests, 54.7% of individuals had this test per-
formed when they were cases of recurrence, 
whereas 66% did so in the initial treatment; 
20.8% (n=11) of cases of recurrence showed 
a BI ≥ 4+ when compared to those in the 
initial treatment [c2 = 8.69 (p = 0.034)]. Of 
all individuals who had a histopathological 
test performed, 49% (n=26) did so to have 
a diagnostic confirmation of recurrence [c2 
= 14.64 (p = 0.001)]. Among the cases as-
sessed for physical disability, there was an 
increase of 17% in the number of cases of 
recurrence with physical disability at level 0, 
when compared to patients assessed at the 
moment of diagnosis (58.5% versus 41.5%). 
In addition, there was an increase of 7.5% of 
physical disability at level 2 between t1 and 
t2 (9.4% versus 1.9%). There was an increase 
in the proportion of cases not assessed for 
physical disability between t1 (45.3%) and 
t2 (22.6%) [c2 = 8.29 (p = 0.040)]. 
There were no statistically significant 
differences between proportions of treat-
ments according to the following variables: 
number, type and location of leprosy le-
sions, nerve thickness, presence and type 
of reactive state and adverse effect (Table 3). 
Discussion
The identification of cases of leprosy 
recurrence with the analysis of clinical and 
laboratory characteristics is key in the adop-
tion of more effective measures to diagnose 
and monitor such cases in specialized 
health clinics. 
The comparison made in this study 
enabled researchers to observe that the 
Table 1 - Distribution of cases of leprosy relapse regarding time interval between initial treatment 
(t1) and relapse (t2), Mato Grosso, 2005-2007.
Tabela 1 - Distribuição dos casos de recidiva em hanseníase, segundo intervalo de tempo entre o 
tratamento inicial (t1) e recidiva (t2); Mato Grosso, 2005-2007. 
Time interval (in years) 
t1 and t2 (n=46)*
Recurrence 
n %
Up to 3 13 28.3
3 to 5 07 15.2
5 to 10 08 17.4
10 and higher 18 39.1
*Sem informação = 7; Média = 7 anos e 6 meses ; Mediana = 3 anos; DP = 5,71
* No information = 7; Mean = 7 years and 6 months; Median = 3 years; SD = 5.71
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dimorphic clinical form was more frequent 
in cases of recurrence, although tubercu-
loid and undetermined clinical forms were 
more frequent during the initial treatment. 
Cases of recurrence were manifested as 
more advanced or severe clinical forms of 
the disease, when compared to those in the 
initial treatment. The majority of cases of 
recurrence were diagnosed with histopatho-
logical tests. A higher proportion of cases of 
recurrence with physical disability at level 0 
was found, although data also show recur-
rence with physical disability at level 2 and 
patients without neurological assessment.
The higher proportion of males at an 
economically productive age was similar 
to other studies5,12,16,20,21. The risk of devel-
opment of leprosy is two times higher in 
men than women22. This characteristic is 
probably associated with the cultural val-
ues of self-care and environmental factors 
involved in the function performed by an 
individual23.
Diagnoses of recurrence observed in the 
early and late periods, when compared to 
the time interval between the initial treat-
ment and occurrence of leprosy recurrence, 
are in agreement with findings from other 
studies15,24-27. Certain factors may influence 
the time interval until recurrence, such as 
Table 2 - Comparison of proportion of cases between initial treatment (t1) and relapse (t2) for 
leprosy, according to clinical and laboratory features, Mato Grosso, 2005-2007.
Tabela 2 - Comparação da proporção de casos entre tratamento inicial (t1) e recidiva (t2) em 
hanseníase, segundo características clínico-laboratoriais; Mato Grosso, 2005-2007. 
Variables 
Leprosy cases
c2 (p value)t1 t2
n % n %
Clinical form
Undetermined 07 13.2 05 9.4 16.06 (0.003)
Tuberculoid 11 20.8 07 13.2
Dimorphic 06 11.3 21 39.6
Virchowian 14 26.4 16 30.2
NA/Ignored* 15 28.3 04 7.5
 Bacilloscopy 
Yes 35 66.0 29 54.7 12.13(0.002)
No 07 13.2 21 39.6
NA/ignored* 11 20.8 03 5.7
BI**
Negative 25 47.2 12 22.6 8.69 (0.034)
0.25 to 3.99 06 11.3 06 11.3
≥ 4 + 04  7.5 11 20.8
NA/Ignored* 18 34.0 24 45.3
Histopathology
Yes 13 24.5 26 49.1 14.64 (0.001)
No 27 50.9 26 49.1
Ignored 13 24.5 01 1.9
LPD ***
Level 0 22 41.5 31 58.5  8.29 (0.040)
Level 1 06 11.3 05 9.4
Level 2 01 1.9 05 9.4
NA/ignored* 24 45.3 12 22.6
* NR/Ignorado = não realizado/ignorado / * NR/Ignorado = not done/unknown 
** IB = índice baciloscópico / ** IB = baciloscopy index
*** GIF = Grau de incapacidade física no diagnóstico / *** GIF = Level of physical incapacity at diagnosis
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clinical form, therapeutic scheme, reac-
tions, irregular treatment and bacillary 
load15,28-30 . 
The higher proportion of diagnoses of 
recurrence categorized in the dimorphic 
clinical form suggests a relationship with 
an individual’s immune response to M. lepra 
and the severity of the disease. A study on 
the interactions between pathogens and the 
immune system in patients with infectious 
diseases has contributed to the investigation 
of the basic regulatory mechanisms of the 
human immune response13,31. In the case of 
leprosy, there is a variety of symptoms that 
are manifested as distinct clinical forms and 
its main characteristic is the type of immune 
Table 3 - Comparison of proportion of cases between initial treatment (t1) and relapse (t2) for 
leprosy, according to clinical characteristics. Mato Grosso, 2005-2007.
Tabela 3 - Comparação da proporção de casos entre tratamento inicial (t1) e recidiva (t2) em 
hanseníase, segundo características clínicas; Mato Grosso, 2005-2007.
Variables 
Leprosy cases
c2 (p value)t1 t2
n % n %
Number of lesions
Up to 5 29 54.7 31 58.5 0.56 (0.454)
More than 5 15 28.3 22 41.5
NA/ignored* 09 17.0 - -
Type of lesion
Macular 09 17.0 10 18.9 1.64 (0.801)
Papular 10 18.9 13 24.5
Infiltrated 03 5.7 02 3.8
Nodule 06 11.3 03 5.7
NA/ignored* 25 47.2 25 47.2
Location of lesion
Face 04 7.5 03 5.7 1.39 (0.846)
Trunk 03 5.7 02 3.8
Limbs 11 20.8 10 18.9
More than one location 03 5.7 06 11.3
NA/ignored* 32 60.4 32 60.4
Nerve thickening
Yes 11 20.8 27 50.9 1.89 (0.170)
No 20 37.7 26 49.1
NA/ignored* 22 41.5 - -
Reactive state 
Yes 18 34.0 22 41.5 0.45(0.502)
No 19 35.8 31 58.5
NA/ignored* 16 30.2 - -
Type of reaction
Type 1 06 11.3 09 17.0 0.54 (0.462)
Type 2 08 15.1 07 13.2
Isolated neuritis 01 1.9 - -
NA/ignored* 38 71.7 37 69.8
Adverse effects 
Yes 07 13.2 13 24.5 0.18 ( 0.670)
No 27 50.9 40 75.5
Ignored* 19 35.8 - -
* NR/Ignorado = não realizado/ignorado / * NR/Ignorado = not done/unknown
579 Rev Bras Epidemiol2012; 15(3): 573-81
Clinical and laboratory characteristics in the retreatment of leprosy relapse
Ferreira, S.M.B. et al.
response between host and pathogen31. For 
this reason, an individual’s resistance to 
M. leprae is specific and suggests a genetic 
component32,33. It is estimated that the ma-
jority of individuals have natural resistance 
to M. leprae (80 to 95%). The remaining 
individuals would be in a borderline state 
of anergy (5%) and could develop the se-
vere forms of this disease. In this case, the 
small number of prime-infected individu-
als develop the disease due to endogenous 
reactivation or due to their receiving a new 
bacillary load (exogenous reactivation)13,31.
It should be emphasized that higher 
percentages were found in the tuberculoid 
and undetermined clinical forms in the 
initial treatment. The clinical forms and, 
consequently, the operational classifica-
tion of the first treatment could have been 
erroneously adopted, which may have led to 
recurrence12,29,30. Thus, if a multibacillary pa-
tient is initially categorized as paucibacillary 
and is treated with PCT/6 instead of PCT/12 
as a result, the probability of occurrence of 
leprosy recurrence is increased. Serological 
tests could function as an alternative tool to 
classify paucibacillary and multibacillary 
leprosy in the first treatment and to confirm 
suspected cases of recurrence34,35.
Histopathological tests are diagnostic 
criteria of recurrence in the majority of stud-
ies, similarly to the present study15,17,18,24,28. 
Although this procedure is important as 
diagnostic support for the confirmation 
of recurrence, bacilloscopy tests are also 
essential, especially in previous multibacil-
lary cases11. Bacillary persistence indicates 
a factor of development of recurrence and 
resulting detection of drug resistance9,21,26,28.
Due to the lack of a test considered to be 
the gold standard to diagnose this disease36, 
referral treatment units need to have other 
resources to accurately diagnose recurrence, 
such as serological tests, morphological 
indices and inoculation tests in mice feet. 
The latter tests, although difficult to be 
performed, enable the viability of M. leprae 
to be observed, tests with chemotherapeutic 
drugs to be monitored, levels of resistance to 
drugs to be verified, and cases of recurrence 
to be confirmed9,10,34,35.
Despite the higher proportion of recur-
rence with physical disability at level 0 at the 
moment of diagnosis showing an improve-
ment in this indicator, the higher frequency 
of patients with physical disability at level 
2 reveals an aggravation of the disease and 
its consequences. However, the data found 
emphasizes the higher prevalence of cases 
ignored/not evaluated for neurological 
assessment. These data suggest the inef-
ficiency of the health service with regard 
to systematic dermato-neurological test 
monitoring. The reappearance of neural im-
pairment is a diagnostic suspicion of the oc-
currence of leprosy recurrence11,12,17. Studies 
indicate that the number of nerves affected 
in the beginning of the treatment, combined 
with other factors, determines the chances 
of occurrence of physical disabilities37.
In conclusion, cases of recurrence 
characterize the aggravation of the disease, 
indicated by the increase in the bacilloscopy 
index and level of physical disability. It is 
recommended that more attention should 
be given to the diagnostic confirmation of 
recurrence, using bacilloscopy tests, espe-
cially in multibacillary cases, and system-
atic neurological assessment of all leprosy 
patients. 
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